

Maintenance treatment with capecitabine and bevacizumab  
(CAIRO3): a phase 3 randomised controlled trial of the D

Lancet, The

385, 1843-1852

DOI: [10.1016/s0140-6736\(14\)62004-3](https://doi.org/10.1016/s0140-6736(14)62004-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	TRIBE study: are all three cytotoxic drugs crucial? Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e578-e579.	5.1	0
2	Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. <i>Oncotarget</i> , 2015, 6, 42396-42410.	0.8	51
3	Rationale for metronomic chemotherapy in phase III trials. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 313-314.	12.5	25
4	A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment. <i>Cancer Journal (Sudbury, Mass )</i> , 2015, 21, 274-283.	1.0	56
5	Are There Strategies to Integrate the Continuum of Care for Metastatic Colorectal Cancer When Resources Are Limited?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 311-316.	1.0	0
6	Maintenance treatment in metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, e582-e583.	5.1	4
7	Maintenance treatment in metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, e583-e584.	5.1	9
8	Maintenance treatment in metastatic colorectal cancer Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e584-e585.	5.1	1
9	First-line chemotherapy for mCRC—a review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 607-619.	12.5	138
10	Clinical overview of metronomic chemotherapy in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 631-644.	12.5	109
11	When less is more: maintenance therapy in colorectal cancer. <i>Lancet</i> , The, 2015, 385, 1808-1810.	6.3	13
12	Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. <i>Science Translational Medicine</i> , 2015, 7, 282ra50.	5.8	48
14	Maintenance therapy for metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, 1444-1445.	5.1	3
15	Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMO3): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1493-1505.	5.1	106
16	Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients. <i>Tumor Biology</i> , 2015, 36, 9031-9037.	0.8	13
17	Design Issues in Randomized Clinical Trials of Maintenance Therapies. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv225.	3.0	18
18	Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1133-1142.	5.1	76
19	Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1355-1369.	5.1	228

#	ARTICLE	IF	CITATIONS
20	Maintenance therapy for metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, 1281-1282.	5.1	2
21	Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1267-1281.	1.1	17
23	Next generation metronomic chemotherapyâ€™ report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6â€™8 May 2016, Mumbai. <i>Ecancermedicalsecience</i> , 2016, 10, 689.	0.6	10
24	Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4113-4120.	1.0	3
25	Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 33418-33428.	0.8	22
26	Liver Metastases in Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e186-e192.	1.8	8
27	Targeting angiogenesis in gastrointestinal tumors: current challenges. <i>Translational Gastroenterology and Hepatology</i> , 2016, 1, 67-67.	1.5	15
28	Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. <i>Oncology Letters</i> , 2016, 12, 3127-3134.	0.8	2
29	Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2016, Volume 6, 21-30.	5.5	8
30	Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. <i>Annals of Oncology</i> , 2016, 27, 1746-1753.	0.6	204
31	Maintenance based Bevacizumab versus complete stop or continuous therapy after induction therapy in first line treatment of stage IV colorectal cancer: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 115-123.	2.0	12
32	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
33	Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as firstâ€™line treatment of patients with advanced HER2â€™negative gastric cancer: A multicenter phase 2 study. <i>Cancer</i> , 2016, 122, 1434-1443.	2.0	31
34	Therapy-activated stromal cells can dictate tumor fate. <i>Journal of Experimental Medicine</i> , 2016, 213, 2831-2833.	4.2	10
35	Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. <i>Annals of Oncology</i> , 2016, 27, 2203-2209.	0.6	25
36	Intermittent versus continuous systemic therapy as treatment for unresectable metastatic colorectal cancer. <i>The Cochrane Library</i> , 0, , .	1.5	0
37	Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study. <i>Clinical Colorectal Cancer</i> , 2016, 15, e165-e174.	1.0	9
38	Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06). <i>Clinical Colorectal Cancer</i> , 2016, 15, 314-320.e2.	1.0	6

#	ARTICLE	IF	CITATIONS
39	Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 659-673.	12.5	154
40	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1091-1108.	1.3	9
41	Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 264-272.	0.6	2
42	Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. <i>Annals of Oncology</i> , 2016, 27, 1273-1279.	0.6	65
43	Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 611-626.	12.5	103
44	Oral drugs in the treatment of metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1351-1361.	0.9	21
45	Combination therapeutics in complex diseases. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2231-2240.	1.6	76
46	Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. <i>Visceral Medicine</i> , 2016, 32, 178-183.	0.5	32
47	Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy. <i>Cancer Research</i> , 2016, 76, 5983-5993.	0.4	46
48	Targeted Therapy of Colorectal Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 796-802.	0.8	38
50	In Vivo Bioorthogonal Chemistry Enables Local Hydrogel and Systemic Pro-Drug To Treat Soft Tissue Sarcoma. <i>ACS Central Science</i> , 2016, 2, 476-482.	5.3	146
51	Pharmacokinetics and Pharmacogenetics of Metronomics. , 2016, , 189-207.		0
52	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066.	2.0	17
53	Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism. <i>Nature Communications</i> , 2016, 7, 12680.	5.8	89
54	Ongoing Adjuvant/Neoadjuvant Trials in Resectable Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 303-313.	1.0	0
55	Systemic Therapy for Metastatic Colorectal Cancer. , 2016, , 275-338.		0
56	Chemotherapy Maintenance. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 199-204.	1.0	31
57	Surefire infusion system versus standard microcatheter use during holmium-166 radioembolization: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 520.	0.7	14

#	ARTICLE	IF	CITATIONS
58	Use of Bevacizumab in the Management of Potentially Resectable Colorectal Liver Metastases: Safety, Pathologic Assessment and Benefit. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 208-216.	1.0	0
59	Expert consensus on maintenance treatment for metastatic colorectal cancer in China. <i>Chinese Journal of Cancer</i> , 2016, 35, 13.	4.9	14
60	From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy. <i>Clinical Colorectal Cancer</i> , 2016, 15, 104-115.	1.0	20
61	A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. <i>Annals of Oncology</i> , 2016, 27, 140-147.	0.6	52
62	Maintenance strategy in metastatic colorectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2016, 42, 82-90.	3.4	53
63	Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 97-104.	3.4	8
64	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 557-571.	1.1	7
65	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. <i>Annals of Oncology</i> , 2016, 27, 843-849.	0.6	46
66	Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 117-126.	2.0	1
68	Cost-effectiveness in colorectal cancer: challenges on quality and comparability. <i>Colorectal Cancer</i> , 2016, 5, 21-31.	0.8	3
69	Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. <i>Annals of Oncology</i> , 2016, 27, 1074-1081.	0.6	72
70	Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2016, 15, e29-e39.	1.0	19
71	Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. <i>Clinical Colorectal Cancer</i> , 2016, 15, 7-15.	1.0	3
72	Antibodies for Treatment of Metastatic Colorectal Cancer. , 2017, , 217-244.		0
73	Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer. <i>Scientific Reports</i> , 2017, 7, 41549.	1.6	13
74	Metronomic and metronomic-like therapies in neuroendocrine tumors – Rationale and clinical perspectives. <i>Cancer Treatment Reviews</i> , 2017, 55, 46-56.	3.4	7
75	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
76	Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer. <i>BMC Cancer</i> , 2017, 17, 132.	1.1	6

#	ARTICLE	IF	CITATIONS
77	The potential clinical promise of "multimodality" metronomic chemotherapy revealed by preclinical studies of metastatic disease. <i>Cancer Letters</i> , 2017, 400, 293-304.	3.2	59
78	Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017, 75, 204-212.	1.3	24
79	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2017, 75, 245-258.	1.3	82
80	Resistance to metronomic chemotherapy and ways to overcome it. <i>Cancer Letters</i> , 2017, 400, 311-318.	3.2	26
81	Metronomic chemotherapy in metastatic colorectal cancer. <i>Cancer Letters</i> , 2017, 400, 319-324.	3.2	33
82	A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer. <i>Cancer Investigation</i> , 2017, 35, 386-392.	0.6	8
83	How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. <i>Annals of Oncology</i> , 2017, 28, 2077-2085.	0.6	30
84	Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. , 2017, , 1-16.		0
85	Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?. <i>Trends in Cancer</i> , 2017, 3, 319-325.	3.8	52
86	Current achievements and future perspectives of metronomic chemotherapy. <i>Investigational New Drugs</i> , 2017, 35, 359-374.	1.2	25
87	Preoperative peripheral blood neutrophil count predicts long-term outcomes following hepatic resection for colorectal liver metastases. <i>Oncology Letters</i> , 2017, 13, 3688-3694.	0.8	7
88	Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. <i>Trends in Cancer</i> , 2017, 3, 529-541.	3.8	84
89	Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. <i>Annals of Oncology</i> , 2017, 28, 1288-1293.	0.6	58
90	Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. <i>European Journal of Cancer</i> , 2017, 76, 93-99.	1.3	54
91	From tumour heterogeneity to advances in precision treatment of colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 235-246.	12.5	466
92	Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2017, 123, 1643-1652.	2.0	48
93	Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review. <i>Annals of Oncology</i> , 2017, 28, 478-486.	0.6	28
95	Survival after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver metastases: A case-matched comparison with palliative systemic therapy. <i>Surgery</i> , 2017, 161, 909-919.	1.0	51

#	ARTICLE	IF	CITATIONS
96	Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. <i>British Journal of Cancer</i> , 2017, 116, 324-334.	2.9	35
97	KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stage IV colorectal cancer patients. <i>Scientific Reports</i> , 2017, 7, 14368.	1.6	13
98	p53 dynamics orchestrates with binding affinity to target genes for cell fate decision. <i>Cell Death and Disease</i> , 2017, 8, e3130-e3130.	2.7	42
99	Development of Orthotopic and Spontaneous Metastatic Human Tumor Xenograft Models for Experimental Therapeutics. <i>Molecular and Translational Medicine</i> , 2017, , 161-182.	0.4	0
100	Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling. <i>Organogenesis</i> , 2017, 13, 183-191.	0.4	3
101	Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 491-501.	0.8	3
102	Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) – Multidisciplinary Management. <i>Colorectal Disease</i> , 2017, 19, 37-66.	0.7	77
103	TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1172-1181.	5.1	111
104	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). <i>ESMO Open</i> , 2017, 2, e000147.	2.0	36
105	Maintenance therapy in advanced colorectal cancer, yes or no? Ask the laboratory. <i>Annals of Oncology</i> , 2017, 28, 2043-2044.	0.6	5
106	Recent developments in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 551-564.	1.4	82
107	Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. <i>British Journal of Cancer</i> , 2017, 117, 1768-1776.	2.9	10
108	The potential role of nintedanib in treating colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1153-1162.	0.9	15
109	Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. <i>Annals of Oncology</i> , 2017, 28, 2128-2134.	0.6	61
110	Personalizing Maintenance Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 205-211.	1.0	1
111	The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902). <i>BMC Cancer</i> , 2017, 17, 243.	1.1	13
112	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	1.1	28
113	Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin <scp>A</scp>merican Group of Osteosarcoma Treatment. <i>Cancer</i> , 2017, 123, 1003-1010.	2.0	42

#	ARTICLE	IF	CITATIONS
114	Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis. <i>Clinical Drug Investigation</i> , 2017, 37, 155-165.	1.1	8
115	Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 106-126.	1.4	36
116	Local Radiotherapy Affects Drug Pharmacokinetics—Exploration of a Neglected but Significant Uncertainty of Cancer Therapy. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 705-716.	0.8	8
117	Continuum of care strategy in metastatic colorectal cancer: a review. <i>Colorectal Cancer</i> , 2017, 6, 95-103.	0.8	0
118	Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	466
121	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017, 23, 4675.	1.4	91
122	Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer. <i>PLoS ONE</i> , 2017, 12, e0174280.	1.1	18
123	Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models. <i>BMC Medical Research Methodology</i> , 2017, 17, 170.	1.4	19
124	Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 273.	0.4	3
125	Discontinuous Schedule of Bevacizumab in Colorectal Cancer Induces Accelerated Tumor Growth and Phenotypic Changes. <i>Translational Oncology</i> , 2018, 11, 406-415.	1.7	20
126	A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e323-e329.	1.0	18
127	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2018, 36, 709-714.	1.2	8
129	Representation of obese participants in obesity-related cancer randomized trials. <i>Annals of Oncology</i> , 2018, 29, 1582-1587.	0.6	20
130	MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1197-1204.	1.2	30
131	Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. <i>European Journal of Cancer</i> , 2018, 91, 99-106.	1.3	61
132	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529.	3.4	87
133	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 251-266.	1.1	41
134	Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series. <i>Oncology Research and Treatment</i> , 2018, 41, 8-13.	0.8	1



#	ARTICLE	IF	CITATIONS
135	Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. <i>Future Oncology</i> , 2018, 14, 1629-1645.	1.1	22
136	Administration of temozolomide: Comparison of conventional and metronomic chemotherapy regimens. <i>Journal of Theoretical Biology</i> , 2018, 446, 71-78.	0.8	9
137	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 672 Tc colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 660-671.	5.1	107
138	Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e99-e107.	1.0	2
139	Reply to M. Mo et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2452-2453.	0.8	0
140	Bevacizumab Maintenance in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2451-2452.	0.8	3
141	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 2052-2060.	0.8	26
142	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). <i>Journal of Clinical Oncology</i> , 2018, 36, 674-681.	0.8	70
143	So Much Data, So Little Knowledge: Using Formal Logic to Aggregate Data and Interpret Information. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, e2-e5.	1.8	0
144	Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer. <i>PLoS ONE</i> , 2018, 13, e0209838.	1.1	6
145	Clinical Efficacy of a Novel Therapeutic Principle, Anakoinesis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1357.	1.6	26
146	Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 395-398.	0.7	0
147	Antiangiogenic Therapy in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 165-170.	1.0	77
149	Treatment of Rectal Cancer in Older Adults. <i>Current Oncology Reports</i> , 2018, 20, 102.	1.8	3
150	Peroxisome Proliferator-Activated Receptors (PPAR) $\gamma$ Agonists as Master Modulators of Tumor Tissue. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3540.	1.8	42
151	Role of Tyrosine Kinases in Gastrointestinal Malignancies. , 2018, , .		1
152	Functional Consequences and Clinical Significance of Tyrosine Kinase Inhibitors in Advanced Colorectal Cancer. , 2018, , 115-140.		0
153	Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. <i>Cancer Epidemiology</i> , 2018, 57, 60-67.	0.8	18

#	ARTICLE	IF	CITATIONS
154	Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practice. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 53-65.	2.0	12
155	The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2018, 50, 562-574.	1.3	16
156	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1451-1463.	0.9	5
157	Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 883-890.	1.0	5
158	Pulmonary Thermal Ablation Enables Long Chemotherapy-Free Survival in Metastatic Colorectal Cancer Patients. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1727-1734.	0.9	24
159	A retrospective study of concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy on curative effect for treatment of patients with N3 stage nasopharyngeal carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 1705-1711.	0.9	18
160	First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. <i>European Journal of Cancer</i> , 2018, 101, 263-272.	1.3	58
161	Integrating Systemic Therapies into the Multimodality Treatment of Resectable Colorectal Liver Metastases. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-4.	0.7	8
162	Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e663-e669.	1.0	9
163	Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 991-1006.	1.1	44
164	An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. <i>International Journal of Cancer</i> , 2018, 143, 2758-2766.	2.3	203
166	Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 909-919.	2.9	42
167	Expression of ILT3 predicts poor prognosis and is inversely associated with infiltration of CD45RO+ T cells in patients with colorectal cancer. <i>Pathology Research and Practice</i> , 2018, 214, 1621-1625.	1.0	9
168	Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial. <i>Clinical Colorectal Cancer</i> , 2018, 17, e733-e739.	1.0	7
169	Cancer as a Systemic Disease That Requires a Systemic Approach. , 2018, , 79-90.		2
170	Maintenance Versus Intermittent Strategies in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis from Another Angle. <i>Advances in Therapy</i> , 2019, 36, 2838-2848.	1.3	1
171	Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , 2019, 51, 1357-1363.	0.4	80
172	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	3.4	70

#	ARTICLE	IF	CITATIONS
173	Metronomic Chemotherapy for Children in Low- and Middle-Income Countries: Survey of Current Practices and Opinions of Pediatric Oncologists. <i>Journal of Global Oncology</i> , 2019, 5, 1-8.	0.5	5
174	Panitumumab Alone for Maintenance Treatment in Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1262.	3.4	3
176	Metronomic Maintenance Therapy for Rhabdomyosarcoma. <i>Trends in Cancer</i> , 2019, 5, 756-759.	3.8	5
177	Precision medicine for metastatic colorectal cancer: an evolving era. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 919-931.	1.4	34
178	Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. <i>PLoS ONE</i> , 2019, 14, e0222580.	1.1	7
179	Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 1395-1403.	2.2	15
181	Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer. <i>Acta Oncologica</i> , 2019, 58, 326-333.	0.8	3
182	Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women. <i>BMC Gastroenterology</i> , 2019, 19, 17.	0.8	4
183	Current Status of Maintenance Systemic Therapies in Metastatic Colorectal Cancer: 2018 Update. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 28-35.	1.0	1
184	Treatment sequencing in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2019, 109, 70-83.	1.3	215
185	Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 412-420.	0.6	6
186	Integrative Omics Analysis Revealed that Metabolic Intervention Combined with Metronomic Chemotherapy Selectively Kills Cancer Cells. <i>Journal of Proteome Research</i> , 2019, 18, 2643-2653.	1.8	8
187	Tumour-Derived Laminin $\hat{\pm}$ 5 (LAMA5) Promotes Colorectal Liver Metastasis Growth, Branching Angiogenesis and Notch Pathway Inhibition. <i>Cancers</i> , 2019, 11, 630.	1.7	52
188	Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 803-813.	2.9	65
189	Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz014.	1.4	10
190	Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience. <i>Journal of Oncology</i> , 2019, 2019, 1-31.	0.6	83
191	Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first-line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study. <i>International Journal of Oncology</i> , 2019, 54, 1433-1445.	1.4	7
192	Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer. <i>Medical Decision Making</i> , 2019, 39, 57-73.	1.2	10

#	ARTICLE	IF	CITATIONS
193	Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study. <i>Tumori</i> , 2019, 105, 243-252.	0.6	2
194	Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Studyâ€”XELAVIRI (AIO KRK0110). <i>Journal of Clinical Oncology</i> , 2019, 37, 22-32.	0.8	35
195	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. <i>Biochemical Pharmacology</i> , 2019, 164, 94-105.	2.0	14
196	Systemic treatment for metastatic colorectal cancer in the era of precision medicine. <i>Journal of Surgical Oncology</i> , 2019, 119, 564-582.	0.8	55
197	Avelumab (antiâ€”PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
198	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	1.3	25
199	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5319.	1.8	34
200	Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer. <i>Medicine (United States)</i> , 2019, 98, e18227.	0.4	11
201	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	0.6	3
202	The pro-tumorigenic host response to cancer therapies. <i>Nature Reviews Cancer</i> , 2019, 19, 667-685.	12.8	135
203	The efficacy and safety of irinotecanâ€”bevacizumab compared with oxaliplatinâ€”bevacizumab for metastatic colorectal cancer. <i>Medicine (United States)</i> , 2019, 98, e17384.	0.4	6
204	Maintenance Therapy in Metastatic Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 615-623.	0.6	4
205	Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissueâ€”Going Beyond Apoptosis Induction. <i>Frontiers in Oncology</i> , 2019, 9, 1408.	1.3	17
206	Recent Advances in the Treatment of Colorectal Cancer. , 2019, , .		2
207	Chemotherapy for Metastatic Colorectal Cancer. , 2019, , 101-111.		1
208	Tumor endothelial cells as a potential target of metronomic chemotherapy. <i>Archives of Pharmacal Research</i> , 2019, 42, 1-13.	2.7	32
209	Panitumumabâ€”based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. <i>International Journal of Cancer</i> , 2019, 145, 576-585.	2.3	21
210	Targeting Angiogenesis in Colorectal Carcinoma. <i>Drugs</i> , 2019, 79, 63-74.	4.9	42

#	ARTICLE	IF	CITATIONS
211	Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. <i>Future Oncology</i> , 2019, 15, 567-577.	1.1	20
212	Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 236.	3.4	36
213	Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 387-400.	0.6	6
214	A Time-Programmed Release of Dual Drugs from an Implantable Trilayer Structured Fiber Device for Synergistic Treatment of Breast Cancer. <i>Small</i> , 2020, 16, e1902262.	5.2	49
215	Feasibility and Safety of CT-Guided High-Dose-Rate Brachytherapy Combined with Transarterial Chemoembolization Using Irinotecan-Loaded Microspheres for the Treatment of Large, Unresectable Colorectal Liver Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 315-322.	0.2	6
216	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, e194489.	3.4	65
217	Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial. <i>Cancer Medicine</i> , 2020, 9, 1033-1043.	1.3	23
218	Maintenance treatment in metastatic colorectal cancer: in search of the best strategy. <i>Clinical and Translational Oncology</i> , 2020, 22, 1205-1215.	1.2	7
219	Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study. <i>Clinical Sarcoma Research</i> , 2020, 10, 18.	2.3	10
220	Clinical Outcomes and Predictors in Patients With Unresectable Colorectal Cancer Liver Metastases Following Salvage Percutaneous Radiofrequency Ablation: A Single Center Preliminary Experience. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382096366.	0.8	3
221	Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAIN - PRODIGE 71 - (FFCD 1710) phase III study. <i>Digestive and Liver Disease</i> , 2020, 52, 1143-1147.	0.4	2
222	Chitosan Hydrogels for Synergistic Delivery of Chemotherapeutics to Triple Negative Breast Cancer Cells and Spheroids. <i>Pharmaceutical Research</i> , 2020, 37, 142.	1.7	8
223	Rethinking clinical oncology drug research in an era of value-based cancer care: A role for chemotherapy pathways. <i>Cancer Medicine</i> , 2020, 9, 5306-5311.	1.3	3
224	Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis. <i>BMC Cancer</i> , 2020, 20, 1149.	1.1	20
225	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 2645-2660.	1.1	1
226	Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 240.	1.0	4
227	Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2020, 3, e2011036.	2.8	6
228	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. <i>Pharmacoeconomics</i> , 2020, 38, 1263-1275.	1.7	3

#	ARTICLE	IF	CITATIONS
229	Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 193.	3.5	46
230	Management of cytotoxic chemotherapy-induced hand-foot syndrome. <i>Oncology Reviews</i> , 2020, 14, 442.	0.8	56
231	Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study. <i>Advances in Therapy</i> , 2020, 37, 2829-2840.	1.3	2
232	Clinical study of XiangShaLiuJunZi decoction combined with S-1 as maintenance therapy for stage III or IV gastric carcinoma and colorectal carcinoma. <i>Medicine (United States)</i> , 2020, 99, e20081.	0.4	10
233	Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. <i>Molecules</i> , 2020, 25, 2614.	1.7	30
234	TRIBE2 results and toxicity. <i>Lancet Oncology, The</i> , 2020, 21, e299.	5.1	0
235	Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. <i>Annals of Surgical Oncology</i> , 2020, 27, 2389-2401.	0.7	16
236	A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer. <i>Trials</i> , 2020, 21, 249.	0.7	2
237	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2020, 21, 497-507.	5.1	196
238	Modified graphene oxide (GO) particles in peptide hydrogels: a hybrid system enabling scheduled delivery of synergistic combinations of chemotherapeutics. <i>Journal of Materials Chemistry B</i> , 2020, 8, 3852-3868.	2.9	22
239	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
240	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 251-270.	1.1	4
241	A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program. <i>Frontiers in Oncology</i> , 2020, 10, 522.	1.3	3
242	Comprehensive review of targeted therapy for colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 22.	7.1	853
243	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020, 135, 230-239.	1.3	11
244	Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. <i>Acta Oncologica</i> , 2020, 59, 395-403.	0.8	6
245	The outcome of primary tumor resection in the unresectable stage IV colorectal cancer patients who received the bevacizumab-containing chemotherapy. <i>Medicine (United States)</i> , 2020, 99, e19258.	0.4	6
246	Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 69-75.	0.3	2

#	ARTICLE	IF	CITATIONS
247	The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 919-928.	2.9	15
248	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGÉ 9 trial. <i>British Journal of Cancer</i> , 2020, 122, 957-962.	2.9	4
249	Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide. <i>Medicine (United States)</i> , 2020, 99, e18591.	0.4	16
250	TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 412-420.	5.1	140
251	Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102877.	2.0	14
252	Recent clinical evidence on metronomic dosing in controlled clinical trials: a systematic literature review. <i>Acta Oncológica</i> , 2020, 59, 775-785.	0.8	11
253	Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era. <i>British Journal of Cancer</i> , 2021, 124, 399-406.	2.9	19
254	Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients. <i>Clinical and Experimental Medicine</i> , 2021, 21, 149-159.	1.9	5
255	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	3.4	2
256	De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103148.	2.0	9
257	Controversies in the treatment of RAS wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 827-839.	1.2	3
258	First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview. <i>Journal of Clinical Medicine</i> , 2021, 10, 470.	1.0	3
259	Diagnosis and Treatment of Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 669.	3.8	941
260	Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer—the Experience of a Tertiary Cancer Center. <i>Frontiers in Pharmacology</i> , 2021, 12, 487316.	1.6	2
261	Recommendations on intervention for hepatobiliary oncological surgery during the COVID-19 pandemic. <i>Cirugía Española (English Edition)</i> , 2021, 99, 174-182.	0.1	1
262	Recomendaciones de actuación en cirugía oncológica hepatobiliopancreática durante la pandemia COVID-19. <i>Cirugía Española</i> , 2021, 99, 174-182.	0.1	4
263	Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis. <i>PLoS ONE</i> , 2021, 16, e0248922.	1.1	1
264	Management of colorectal cancer in the era of COVID-19: Challenges and suggestions. <i>Science Progress</i> , 2021, 104, 0036850421110106.	1.0	12

#	ARTICLE	IF	CITATIONS
265	Cancer clinical trial vs <scp>realâ€world</scp> outcomes for standard of care <scp>firstâ€line</scp> treatment in the advanced disease setting. <i>International Journal of Cancer</i> , 2021, 149, 409-419.	2.3	6
266	Efficacy of modified bevacizumab-XELOX therapy in Japanese patients with stage IV recurrent or non-resectable colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 527-534.	0.6	3
267	Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer. <i>BMC Gastroenterology</i> , 2021, 21, 184.	0.8	0
268	Maintenance in gastric cancer: New life for an old issue?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103307.	2.0	4
269	A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research. <i>Cancer Treatment Reviews</i> , 2021, 95, 102174.	3.4	15
270	Metronomic Chemotherapy. <i>Cancers</i> , 2021, 13, 2236.	1.7	38
271	Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients. <i>Materials</i> , 2021, 14, 2440.	1.3	14
272	Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study. <i>World Journal of Clinical Oncology</i> , 2021, 12, 355-366.	0.9	8
273	Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics. <i>Cancer Medicine</i> , 2021, 10, 4781-4789.	1.3	6
274	Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103346.	2.0	9
275	What is the real value of metronomic chemotherapy in the treatment of gastrointestinal cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2297-2302.	0.9	2
276	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patientsâ€™ data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , 2021, 97, 102202.	3.4	14
277	Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 55.	1.3	4
278	Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. <i>Clinical Colorectal Cancer</i> , 2021, 20, 153-160.	1.0	3
279	Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies. <i>Drugs and Aging</i> , 2021, 38, 639-654.	1.3	1
280	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3504.	1.7	5
281	Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3242-3250.	0.8	35
282	Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma. <i>Lancet, The</i> , 2021, 398, 278-279.	6.3	5



#	ARTICLE	IF	CITATIONS
283	Pharmacogenomicâ€Guided Therapy in Colorectal Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 616-625.	2.3	14
284	Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis. <i>Cancer Research and Treatment</i> , 2021, 53, 703-713.	1.3	1
285	Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 303-313.	6.3	98
286	Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial). <i>International Journal of Colorectal Disease</i> , 2021, 36, 2637-2647.	1.0	1
287	Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward. <i>Cancers</i> , 2021, 13, 3926.	1.7	25
288	Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102226.	3.4	8
289	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3693-3704.	0.8	19
290	Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). <i>Journal of Clinical Oncology</i> , 2022, 40, 72-82.	0.8	42
291	Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 194-198.	0.5	1
292	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e1704-e1729.	1.9	14
293	Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 641044.	1.3	2
294	Treatment Holidays for Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01999.	0.8	1
295	Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer. <i>Value in Health</i> , 2021, 25, 104-115.	0.1	2
296	Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy. <i>Oncology Research</i> , 2021, 28, 701-714.	0.6	5
297	Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. <i>ESMO Open</i> , 2021, 6, 100246.	2.0	11
298	Capecitabine as Maintenance Therapy for High-Risk, Resected Colorectal Cancer. <i>Gastrointestinal Tumors</i> , 2021, 8, 81-86.	0.3	2
299	The optimal cutâ€off values for tumor size, number of lesions, and CEA levels in patients with surgically treated colorectal cancer liver metastases: An international, multiâ€institutional study. <i>Journal of Surgical Oncology</i> , 2021, 123, 939-948.	0.8	14
300	Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 65-72.	1.0	14

#	ARTICLE	IF	CITATIONS
301	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	1.0	16
302	COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , 2020, 52, 597-603.	0.4	37
303	Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of Therapy. <i>Seminars in Interventional Radiology</i> , 2017, 34, 116-120.	0.3	3
304	Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients. <i>Medicine (United States)</i> , 2020, 99, e23719.	0.4	6
305	Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note. <i>PLoS ONE</i> , 2016, 11, e0158034.	1.1	21
306	Metronomic chemotherapy offsets HIF1 $\alpha$ induction upon maximum-tolerated dose in metastatic cancers. <i>EMBO Molecular Medicine</i> , 2020, 12, e11416.	3.3	20
307	Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature. <i>Medicine and Pharmacy Reports</i> , 2018, 91, 12-17.	0.2	10
308	Roles of long noncoding RNAs in colorectal cancer metastasis. <i>Oncotarget</i> , 2017, 8, 39859-39876.	0.8	85
309	Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. <i>Oncotarget</i> , 2017, 8, 55715-55730.	0.8	76
310	Who will benefit more from maintenance therapy of metastatic colorectal cancer?. <i>Oncotarget</i> , 2018, 9, 12479-12486.	0.8	5
311	Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11b <sup>high</sup> /Gr1 <sup>high</sup> myeloid cells. <i>Oncotarget</i> , 2018, 9, 17620-17630.	0.8	9
312	The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2020, 15, 257-269.	0.8	3
313	Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. <i>International Journal of Molecular Sciences</i> , 2021, 22, 130.	1.8	160
314	Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1188-1196.	0.7	3
315	Colorectal Cancer: Metastatic Disease. <i>UNIPA Springer Series</i> , 2021, , 617-633.	0.1	0
316	Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 733955.	1.3	3
317	Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , 2021, 11, 712053.	1.3	5
318	On the New Payment-by-Results Method for Determining the Fair Price of New Drugs. An Application in Oncology. <i>Global &amp; Regional Health Technology Assessment</i> , 2016, 3, GRHTA.5000233.	0.2	0

#	ARTICLE	IF	CITATIONS
320	CHEMOTHERAPY IN THE MANAGEMENT OF LOCALIZED AND METASTATIC COLON CANCER: NEW AND YET UNFORGOTTEN APPROACHES. Meditsinskiy Sovet, 2017, , 67-76.	0.1	2
321	Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer. Oncotarget, 2018, 9, 2876-2886.	0.8	1
322	Kolorektales Karzinom. , 2018, , 273-341.		0
323	The application of the modern target medications for the treatment of metastatic colorectal cancer. Russian Journal of Evidence-Based Gastroenterology, 2018, 7, 21.	0.3	1
324	Molecular Target Therapy for Digestive Malignancy. Nihon Ika Daigaku Igakkai Zasshi, 2018, 14, 169-172.	0.0	0
325	EFFECTIVENESS OF MAINTENANCE THERAPY AFTER THE END OF THE FIRST LINE OF TREATMENT FOR PATIENTS WITH METASTATIC COLORECTAL CANCER – THE RESULTS OF A POPULATION-BASED STUDY. Malignant Tumours, 2018, 8, 57-67.	0.1	0
326	Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. , 2019, , 379-394.		0
327	Metastatic Colorectal Cancer. , 2019, , 135-160.		0
328	Faut-il prendre en compte la localisation du primitif dans la prise en charge du cancer colorectal métastatique ?. Colon and Rectum, 2019, 13, 104-107.	0.0	0
329	Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims. Current Cancer Therapy Reviews, 2019, 15, 184-191.	0.2	0
330	Prognosis and Management of Recurrent Metastatic Colorectal Cancer. , 2020, , 571-587.		0
331	Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. International Journal of Molecular Sciences, 2021, 22, 11780.	1.8	7
332	Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy. Cancers, 2021, 13, 49.	1.7	7
334	Patients Living Longer With Metastatic Colorectal Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, 286-288.	0.2	0
335	Metronomic paclitaxel improves the efficacy of PD-1 monoclonal antibodies in breast cancer by transforming the tumor immune microenvironment. American Journal of Translational Research (discontinued), 2020, 12, 519-530.	0.0	11
336	Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. Molecular Diagnosis and Therapy, 2021, 25, 715-734.	1.6	6
337	An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans. European Journal of Cancer, 2022, 161, 138-147.	1.3	6
338	Metronomic chemotherapy and antiangiogenic drugs: Preclinical and clinical data. , 2022, , 127-146.		0

#	ARTICLE	IF	CITATIONS
339	Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2022, 21, e162-e170.	1.0	5
340	Emerging actionable targets to treat therapy-resistant colorectal cancers. <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2022, 5, 36-63.	0.9	6
341	Precision medicine for metastatic colorectal cancer in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110727.	1.4	23
342	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 198-209.	1.9	18
343	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with <i>RAS</i> Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. <i>Oncologist</i> , 2022, 27, e29-e36.	1.9	3
344	The sequence of antiVEGF(R) preparations in the treatment of metastatic colorectal carcinoma in 2020. <i>Onkologie (Czech Republic)</i> , 2021, 14, 263-267.	0.0	0
345	Surgical timing after preoperative chemotherapy is associated with oncologic outcomes in resectable colorectal liver metastases. <i>Journal of Surgical Oncology</i> , 2022, , .	0.8	2
346	Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of <i>RAS</i> mutant metastatic colorectal cancer. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 531-538.	0.7	3
347	Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC. <i>Future Oncology</i> , 2022, 18, 2155-2171.	1.1	4
348	The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 870395.	1.6	6
349	Efficacy, Molecular Biology, Quality of Life, or Economic Aspects: What Do We Really FOCUS on?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1260-1262.	0.8	2
350	Treatment Break Versus Maintenance in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1262-1263.	0.8	2
351	Reply to A. Kurreck et al and M.S. Copur et al. <i>Journal of Clinical Oncology</i> , 2022, 40, 1263-1264.	0.8	0
353	Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives.. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 771-785.	0.3	1
354	Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study. <i>Clinical Cancer Research</i> , 2022, 28, 2818-2829.	3.2	12
355	Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis. <i>Asian Journal of Oncology</i> , 0, , .	0.2	0
356	Clinical management of metastatic colorectal cancer in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 372-401.	157.7	167
357	Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with <i>RAS</i> / <i>BRAF</i> wild-type metastatic colorectal adenocarcinoma as the first-line therapy. <i>BMC Medicine</i> , 2022, 20, 155.	2.3	9

#	ARTICLE	IF	CITATIONS
358	Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study. <i>European Journal of Cancer</i> , 2022, 169, 166-178.	1.3	0
359	Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 2783.	1.0	6
360	Maintenance therapy for long-term control of high-grade endometrial stromal sarcoma. <i>BMJ Case Reports</i> , 2022, 15, e248971.	0.2	1
361	Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature. <i>Journal of Clinical Medicine</i> , 2022, 11, 2849.	1.0	4
362	Clinical Updates for Colon Cancer Care in 2022. <i>Clinical Colorectal Cancer</i> , 2022, 21, 198-203.	1.0	32
363	Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. <i>Journal of Cancer Policy</i> , 2022, , 100342.	0.6	1
364	Hláu†U QUáºc Cá»   A CAPECITABINE ÄÄEN CHáºT TRONG ÄÄá»€U TRá»Š DUY TRÁCE UNG THÄE ÄÄºI TRá»°C TRÄ€NG D  CÄ, N TáºI Bá»†NH Nam, 2022, 515, .	0.0	0
365	MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer. <i>ESMO Open</i> , 2022, 7, 100559.	2.0	16
366	Targeting Gastric Cancer Stem Cells to Enhance Treatment Response. <i>Cells</i> , 2022, 11, 2828.	1.8	18
367	The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer. <i>Life</i> , 2022, 12, 1552.	1.1	0
368	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
369	Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 10-32.	0.6	316
370	Timeâ€varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: a populationâ€based study and metaâ€analysis. <i>International Journal of Cancer</i> , 0, , .	2.3	2
371	BRAFV600E in colorectal cancer reduces sensitivity to oxidative stress and promotes site-specific metastasis by stimulating glutathione synthesis. <i>Cell Reports</i> , 2022, 41, 111728.	2.9	3
374	Efficacy and safety of metronomic chemotherapy in maintenance therapy for metastatic colorectal cancer: A systematic review of randomized controlled trials. <i>Medicine (United States)</i> , 2022, 101, e31659.	0.4	2
375	Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 7523.	1.0	1
376	Demystifying BRAF Mutation Status in Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2023, 278, e540-e548.	2.1	6
377	Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. <i>Efficacy and Mechanism Evaluation</i> , 2022, 9, 1-92.	0.9	1

#	ARTICLE	IF	CITATIONS
378	New developments in targeted therapy for metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211485.	1.4	8
379	Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. <i>Cancers</i> , 2023, 15, 900.	1.7	3
380	Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review. <i>Current Oncology Reports</i> , 2023, 25, 341-352.	1.8	2
381	Stage IV Colorectal Cancer Management and Treatment. <i>Journal of Clinical Medicine</i> , 2023, 12, 2072.	1.0	18
382	Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2023, 38, .	1.0	2
383	Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer. <i>ESMO Open</i> , 2023, 8, 101199.	2.0	2
384	Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAFV600E mutation status. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 7819-7829.	1.2	1
385	Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives. <i>Pharmaceutics</i> , 2023, 15, 1192.	2.0	6
386	Retrospective analysis of colorectal cancer patients with metachronous initially unresectable liver metastases (and no other) achieving no evidence of disease after first-line comprehensive therapy: a multicenter real-world study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 8403-8413.	1.2	0